Panbela Therapeutics Inc. (NASDAQ:PBLA) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET

Company Participants

James Carbonara – Managing Partner-Hayden IR, Inc.

Jennifer Simpson – Chief Executive Officer

Sue Horvath – Chief Financial Officer

Conference Call Participants

Robin Garner – Craig-Hallum

Tony Butler – Roth Capital

Operator

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Panbela Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After management's prepared remarks, there will be a question-and-answer session.

I would now like to turn the call over to the host, James Carbonara, Investor Relations of Hayden. Please go ahead.

James Carbonara

Thank you, and once again, welcome to Panbela’s first quarter 2022 earnings call. With me on the call are Jennifer Simpson, Chief Executive Officer; and Sue Horvath, Chief Financial Officer.

Before I turn the call over to Dr. Simpson, please note that statements made on this call that are not historical facts may be forward-looking statements. Significant risks and uncertainties that could cause actual results to differ from those expressed or implied in the forward-looking statements are detailed in the company's annual report on Form 10-K and supplemented by subsequently filed quarterly reports on Form 10-Q as well as in other reports that the company has filed with the SEC. Any forward-looking statements made on this call are made only as of today's date and the company does not undertake any obligation to update or supplement any such statements to reflect subsequent developments.

Now, I would like to turn the call over to Jennifer Simpson, CEO of Panbela. Jennifer, please proceed.

Jennifer Simpson

Thank you, James. And thank you everyone for joining. I will begin the call by touching on Q1 and our recent significant accomplishments. Sue will then follow with the review of the financial results, and then we will open it up for Q&A. So starting with Q1 and recent highlights, as we highlighted on our last earnings call in February, we entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals Incorporated, or CPP for short. A closing is expected to occur in the second quarter of 2022 subject to the satisfaction of customary closing conditions.

As we've shared, the combined company will have a much larger pipeline, targeting approximately a $5 billion aggregate market opportunity for the areas of initial focus. Acquiring CPP will substantially advance our mission of treating diseases, where there is an unmet need through a diversified pipeline, addressing numerous targets and thus expanding the potential of the combined company. During the SBP-101, just last week, we held an R&D Day and we were joined by leading experts from The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine for a deep dive on SBP-101 as a polyamine metabolism modulator in ovarian cancer.